Ronak Gandhi is a Rheumatology/Immunology physician affiliated with The University of Texas Medical Branch at Galveston. OpenAlex indexes 44 publications with 692 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
400 Harborside Drive Suite 100
Galveston, TX 775555302
Telephone
409-772-0755Provider last certified this registry record 16 Mar 2026.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202517 payments
- Amgen Inc.Program year20258 payments
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.6%Folate Analog Metabolic Inhibitor18.3%Methotrexate100%Part D≥30 patientsJAK inhibitor10.1%Rinvoq100%Part D<11 patients+ 2 more classes in this area
Antiparasitic
26.3%Antimalarial26.3%Hydroxychloroquine Sulfate100%Part D≥43 patientsMetabolism & gastrointestinal
20.1%Corticosteroid12.7%Prednisone100%Part D≥18 patientsAminosalicylate4.1%Sulfasalazine Dr100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Targeted quadruple therapy in anti‐MDA5 positive dermatomyositis with orbital and pulmonary complications
Rheumatology & autoimmunity
2025 - Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Antonio Bianco, MD
The University of Texas Medical Branch at Galveston
William Calhoun, MD
The University of Texas Medical Branch at Galveston
Shawn Nishi, MD
The University of Texas Medical Branch at Galveston
Xiang Fang, MD, PhD
The University of Texas Medical Branch at Galveston
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”